| |
ENANTA HCV PROGRAMS
|
| |
| |
HCV Protease Inhibitor Program
Enanta has developed significant expertise and know-how in the field of HCV protease inhibitors. The Company has established an SAR strategy to create novel and proprietary series and leads that demonstrate significant anti-viral potency in the enzyme and cell-based replicon assay. Further, Enanta has created and continues to grow its substantial and unique IP position in the HCV protease arena.
Enanta has identified many promising lead series and several lead candidates that have sub nM potency in the replicon assay, good bioavailability, attractive drug levels at the site of infection, and potential for QD dosing. Enanta has announced the advancement of this program into phase 2 clinical trials.
In December 2006, Enanta and Abbott formed a worldwide alliance for the development of these protease inhibitors (click here for more). Enanta retains a 40% profit share option in the United States and has royalty streams in non-U.S. territories.
HCV NS5A Inhibitor Program
Enanta has a robust drug discovery effort in NS5A inhibitors. Our researchers have identified multiple lead series with significant anti-viral potency (picomolar range) with favorable preclinical pharmacokinetic properties amenable for QD dosing. By leveraging our medicinal chemistry expertise, Enanta is building a vast intellectual property position on NS5A inhibitors. Enanta is currently advancing this program independently.
HCV Polymerase Inhibitor Program
Enanta has a small molecule drug discovery effort underway on nucleoside and non-nucleoside polymerase inhibitors. The distinct mechanism of action and mutation resistance profile between a protease and polymerase inhibitor makes this combination ideal for potential use in a small molecule cocktail therapy.
Our researchers have identified a promising lead series with significant anti-viral potency in vitro with favorable preclinical pharmacokinetic properties. The company is building its intellectual property position and advancing this program independently.
HCV Cyclophilin Program
Enanta's research activities have identified cyclophilin binders that inhibit HCV replication. Enanta has extensive chemistry expertise on small molecules that are active cyclophillin binders.
Our efforts in screening internal compounds and the study of SAR in anti-HCV activity are ongoing. The company is building its intellectual property position and advancing this program independently.
Other HCV Programs
Enanta has additional undisclosed breakthrough HCV discovery efforts underway, leveraging the company's core expertise in advanced medicinal chemistry.
|
|
| |
| |
|
|
|
